The Chinese Red Cross Foundation Rare Disease Mutual Assistance Fund Officially Launches

CANbridge Participated in the Ceremony as a Founding Sponsor

BEIJING & CAMBRIDGE, Mass.–(BUSINESS WIRE)–CANbridge Pharmaceuticals, Inc. (“CANbridge” or the “company,” stock code 1228.HK), a leading China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies, announced that James Xue, Ph.D., Founder, Chairman and CEO, attended the launch ceremony of the Chinese Red Cross Foundation (CRCF) Rare Disease Mutual Assistance Fund, at the China Rare Diseases Conference 2021, in Beijing, on December 18^th, as the representative of CANbridge, one of the founding sponsors of the Fund.

December 18, 2021 marked the opening of China Rare Disease Conference 2021, organized by the China Alliance for Rare Diseases (CHARD), the Chinese Red Cross Foundation (CRCF), the China Pharmaceutical Innovation and Research Development Association (PhIRDA) and the Chinese Hospital Association (CHA). The conference was co-organized by the Peking Union Medical College Hospital (PUMCH) and the Office of the National Collaborative Network for the Diagnosis and Treatment of Rare Diseases, under the guidance of the National Health Commission (NHC) and the Red Cross Society of China (RCSC).

At the CRCF Rare Disease Mutual Assistance Fund launch ceremony, CRCF President, Changjiang Guo, acknowledged the first corporate sponsors with certificates. The ceremony shared the stage with the launch ceremony for the central government’s Lottery Charity Fund, dedicated to the development of rare disease diagnosis and treatment capabilities nationwide. Both ceremonies were presided over by Jinguo He, Director of the NHC Department of Finance; Yanhong Guo, Ombudsman of the NHC Bureau of Medical Administration; Peixin Wu, Vice President of PUMCH, and Linkang Li, Executive Director General of CHARD.

“We are honored to participate in the launch of the CRCF Rare Disease Mutual Assistance Fund,” said James Xue, Ph.D., CANbridge Founder, Chairman and CEO. “It is an important part of our corporate social responsibility (CSR) and our ongoing commitment to building a rare disease ecosystem to improve treatment, care and support for Chinese rare disease patients and reduce the financial burden on families. Together with other organizations, including CHARD, CRCF and other patient advocacy groups, CANbridge will launch a wide range of rare disease patient support initiatives designed to elevate treatment and care to the next level in China.”

About CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. (“CANbridge,” stock code: 1228.HK) is a China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies.

CANbridge has a comprehensive and differentiated pipeline of 13 drug assets with significant market potential, targeting some of the most prevalent rare diseases and rare oncology. These include Hunter syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, rare cholestatic liver diseases and neuromuscular diseases, as well as glioblastoma multiforme (GBM).

CANbridge strategically combines global collaborations and internal research to build and diversify its drug portfolio and invest in next-generation gene therapy technologies for rare disease treatments. CANbridge global partners include, but are not limited to, Apogenix, GC Pharma, Mirum, Wuxi Biologics, Privus, the University of Massachusetts Medical School (UMass), the University of Washington School of Medicine, LogicBio and Scriptr.

For more on CANbridge Pharmaceuticals Inc., please go to: www.canbridgepharma.com.

Contacts

CANbridge Pharmaceuticals Inc.

[email protected]
Media:

Deanne Eagle

Planet Communications

[email protected]
917.837.5866